ProKidney
ProKidney's revenue rose 1075.0% to $1 million in fiscal 2025. Its operating margin was −18,477.8%, up from −241,679.0% a year earlier. Free cash flow was −$135 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
ProKidney lost money in fiscal 2025: a net loss of $69 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 21 | 490 | 61 | 99 | 108 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | −711.7x | −12,626.8x | −20,408.4x | −41,251.8x |
| Current ratio | 2.2x | 46.4x | 14.9x | 10.9x | 9.1x |
| Quick ratio | 2.2x | 46.4x | 14.9x | 10.9x | 9.1x |
Cash flow
Projections
Project ProKidney's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought ProKidney shares on the open market, and 1 insider sold $1.1 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Brian JG PereiraDirector | Sold | 250,000 | $1.42 | $355,000 | Form 4 |
| Aug 19, 2026 | Brian JG PereiraDirector | Sold | 250,000 | $1.44 | $360,000 | Form 4 |
| Aug 18, 2026 | Brian JG PereiraDirector | Sold | 257,164 | $1.37 | $352,315 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | −14,077.6% |
| Altman Z'' | −45.47 | −32.82 | −41.28 |
| Accruals ratio | 11.6% | 15.1% | 13.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Fail | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | — | — | — |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put ProKidney side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| ProKidney | FY25 | 1,075.0% | −18,477.8% | −15,152.6% | — | — | — | |
| Rallybio | FY25 | 34.9% | −3,853.6% | — | — | — | — | Compare |
| Pluri | FY26 | −23.9% | −2,454.5% | −1,990.3% | — | — | — | Compare |
| Shattuck Labs | FY25 | −82.5% | −5,150.8% | −3,995.3% | — | — | — | Compare |
| ImageneBio | FY25 | −77.1% | −6,056.4% | — | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | 0 | 0 | 0 | 1 |
| Revenue growth | — | — | — | — | — | 1,075.0% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 21 | 46 | 82 | 107 | 128 | 114 |
| Operating income | −27 | −55 | −153 | −152 | −184 | −165 |
| Net income | −27 | −55 | −148 | −36 | −61 | −69 |
| Diluted EPS (US$) | — | — | −0.23 | — | — | — |
| Diluted shares (millions) | — | — | 62 | — | — | — |
| Cash flow | ||||||
| Cash from operations | −25 | −50 | −77 | −90 | −126 | −120 |
| Capital expenditure | 6 | 5 | 2 | 34 | 30 | 15 |
| Free cash flow | −31 | −55 | −79 | −124 | −156 | −135 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 10 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 74 | 31 | 29 | 25 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 5 | 21 | 490 | 61 | 99 | 108 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | — | 40 | 518 | 421 | 441 | 336 |
| Total liabilities | — | 13 | 13 | 29 | 39 | 35 |
| Shareholders' equity | 10 | 27 | −1,097 | −1,103 | −995 | −1,011 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | −241,679.0% | −18,477.8% |
| Net margin | — | — | — | — | −80,507.9% | −7,725.2% |
| Free cash flow margin | — | — | — | — | −205,079.0% | −15,152.6% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −14,077.6% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | — | — | — | — | — |
| Return on assets | — | — | −53.1% | −7.6% | −14.2% | −17.8% |
| Net debt to EBITDA | — | — | — | — | — | — |